Received Mar 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | Y013583 | OT / LA |
they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration; This spontaneous report was received from a registered nurse referring to a 6-year-old female patient. The patient's concomitant drugs included Hepatitis a vaccine inact (HAVRIX) and Diphtheria vaccine toxoid;Hepatitis b vaccine rHBsAg (yeast) (+) Pertussis vaccine acellular 3-component (+) Polio vaccine inact 3v (Vero) (+) Tetanus vaccine toxoid (PEDIARIX). The patient's medical history, historical drugs, past drug reactions or allergies, and concurrent conditions were not reported. On 01-OCT-2024, the facility received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accommodate the shipment. The reporter was unaware that there were two Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), It was assumed that the Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) received could be refrigerated and were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. On 04-DEC-2024, the patient was vaccinated with the first dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) injection (lot#: Y013583, expiration date: 03-FEB-2026; strength and dose were not reported) subcutaneously in the left arm for prophylaxis (product storage error). This case was received from the same reporter with the case US-009507513-2254349.
HAVRIX; PEDIARIX; sterile diluent